The use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mTOR) complexes

Details for Australian Patent Application No. 2011213649 (hide)

Owner The Administrators of the Tulane Educational Fund

Inventors Coy, David H.; Maderdrut, Jerome L.; Li, Min; Batuman, Vecihi

Agent Pizzeys

Pub. Number AU-A-2011213649

PCT Pub. Number WO2011/097581

Priority 61/337,679 05.02.10 US

Filing date 7 February 2011

Wipo publication date 11 August 2011

International Classifications

A61K 38/13 Medicinal preparations containing peptides

A61K 38/16 Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 38/17 Medicinal preparations containing peptides - from animals

A61P 25/00 Drugs for disorders of the nervous system

A61P 35/00 Antineoplastic agents

A61P 37/00 Drugs for immunological or allergic disorders

Event Publications

23 August 2012 PCT application entered the National Phase

  PCT publication WO2011/097581 Priority application(s): WO2011/097581

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011213655-Methods and devices for improved oxygen permeability in microorganism storage container

2011213631-Biomineral and metal binding liposomes, their synthesis, and methods of use thereof